Member Info for Uncanny

Simon, you are spot on, but a rights issue or placing pro rata investors can cost over £100k. Placing shares with their nomad would cost probably no more than £10k. The question you ask, is would you rather this saving be used to accelerate compound development? At the current fund raise rate of 1.5p you can buy shares at the same price as the last placing price. The otehr risk you have is that the offer is not successful and then have to fund an underwriter to yake ip the slack. As much as we criticise, the nomad will advise VAL on the most cost effective method of fund raise and what will be the most successful. When you buy a developmental bio, uou have accept that the cash burn is great, fund raise is inevitable and dilution will naturally occur. My goodness, I wish it didn’t but its a necessary evil to get to the end of result of commercialisation, strong balance sheet and an income stream.

Adam, I have been in fund raises and its not easy to navigate, especially when you have no invome stream in the near term and that the money consumption is quite severe. If you’re a Galxo, no problem, if you’re a junior bio with a my cap of -£10mn, then its a case of beggars can’t be choosers and they can only sell their wares on the success of their compound testing to date. Beasically, it is what it is and taht’s the risk we take. GLA

Adam, I understand your point, but raising cash is the only way the company survives to get to key inflection points in terms of commercialisation. Without the fund raising we would not have pre-clinical 101 and 301, or Pl/ll 201 or the soon TBA 401 JV deal / commercialisation. Its a sad symptom of a junior bio’s journey, but VERY necessary. The end goal like 401 is to get a cash injection and a sugar daddy that will take the compound forward to market with hopefully milestone payments and a 10% sales royalties like the example in the Align research, to VAL. There is no shareholder value at present except for patented compounds - the assets uou could say. Shareholder value will come with and only with commercialisation of its compounds.

Draey The Georgian authorities do not need to approve Plll, just raise any concerns or questions they may have going forward - just had that confirmed BTW.

I see the report under VAL’s diary shows that the readout for 201 should be coming in this quarter, so fingers crossed things still on track in their update, as this is the big one, albeit we don’t know what 401 will bring - we might get a pleasant surprise for Xmas!

I am hoping this month for news ahead of the conference. 401 deal must be pretty much imminent. Have a read of the Align research to keep the focus and forget the drivel on this BB. GLA

Makes no difference VALISEEK / VAL has the IP and is commercialising..... end of.

People too quick to write off 401: “According to a March 2017 report from Grand View Research, the global non-small cell lung cancer therapeutics market is expected to reach a value of $12.2 billion by 2025.“ “Mologen (Frankfurt: MGN) announced the signing of a license deal for the Chinese territory and a global co-development agreement with Oncologie Inc. for its lead compound lefitolimod, which is currently being developed within the framework of a pivotal study for first line maintenance therapy for colorectal cancer. Key data of its phase II IMPULSE study in small cell lung cancer were announced in April 2017. The agreement includes the development, manufacture and commercialization of lefitolimod in China and a planned global co-development program. Mologen received an initial payment of €3 million, with a €2 million equity investment, due within 12 months. Development and commercialisation milestones can amount to above €100 million and will be paid over several years. Additionally, Mologen will receive low double digit royalties on sales.” Align: “ValiRx is making good progress in the clinic with its two lead candidates. The signing of a value enhancing deal with a development/commercial partner for VAL401 particularly, but also for VAL201, looks not far off, as has been flagged by the company in recent RNSs. We believe that given the current late stage of 401 in Phase III trials and the very real likelihood of a partnership deal on the near horizon that the current post recent placing price of sub 2p provides an excellent opportunity to enter into the stock in anticipation of such catalysts and that a re-rating to a realistic level is now overdue. As has been evidenced before on positive trial RNSs, such news we believe would trigger a large rise in the share price. Additionally, as well as cementing value within the development portfolio, we would expect that any such partnership deal would include a funding element as well as attract institutional investment, thus reducing the market’s concerns over this major risk to the investment case and putting ValiRx into a higher league.”

SCAP playing silly buggers again! Another 101, 201, 301, 401 - perhaps the final flush out?

We have 4 things here, all postive..... 1. Stock overhang from the placing at 1.5p - looks like SCAP moving the spread around which makes me think they have the sell order of the placing shares for the broker - all other MM’s keeping a distance. 2. Yes Cobalt, maybe 1p or +10p soon if we get an extraordinary 401 deal, lets see. 3. Waiting on news now, but everyone has discounted 401, but we’re not scientists nor is the market. We need to see numbers and £’s 4. 201 is the bone shaker (probably wrong analogy) but should get an update soon before June’19 and the straw that breaks the camels back in terms of share price. Still loading up as confident in the science. People here get on their high horse about the business acumen of the directors, but the BoD have employed pro negotiators to get the best deal. GLA

Another 401 trade - JV leak or having a larf!?

Isle, your about the same as me c. 50% down, but a bit of good news and we’ll be back in to the 3’a and 4’s in no time. I think the market are just waiting for the first commercialisation being 401 JV to appease the funding issue and then we should be off and running with cash injection and milestone payments. GLA

I think the margin traders have been hit today! Sorry, but happy to pick up cheap stock today. GLA

The original funny trades made way to 2 x RNS’s - 401 and 201, then the last one led to 1 X RNS - Align research. What will todays 401, 301, 201, 101 trades lead to next week (if anything)?

Just topped up today and now have my target holding. ;@D

SK, circa 10p is my fair value. Just need the RNS now! Looks like Valigenx was a red herring re: 401 - I have a similar email from VAL to say that it is quite normal for quoted companies to set up shell companies in anticpation of future developments - wonder what though?! I hope the 401 JV company is more substantial than Mystic.”

Valju, just filter the lot of them mate.

Thanks Bwgs. Yes, this I think is good news and perhaps a new structure to reverse one of our compounds in to for a large sum hopefully!

What exactly is the structure? Is it on companies house anyone?

SK I have him on filter but, yes, his position is threatened now!